174722-31-7
174722-31-7 structure
- Name: Rituximab
- Chemical Name: Rituximab
- CAS Number: 174722-31-7
- Molecular Formula: C6416H9874N1688O1987S44
- Molecular Weight:
- Catalog: API Antineoplastic agents Other antineoplastic agents
- Create Date: 2019-01-24 18:36:57
- Modify Date: 2024-01-05 11:33:29
-
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1].
| Name | Rituximab |
|---|
| Description | Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Rituximab (anti-CD20) inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab (anti-CD20) induces high CDC killing of follicular lymphoma cells[2]. |
| In Vivo | A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. |
| References |
| Molecular Formula | C6416H9874N1688O1987S44 |
|---|